GLP-1 receptor agonists are no longer "diabetes drugs that also reduce weight." They are an emerging cardiometabolic class with peer-reviewed efficacy across at least six conditions — and the trial program is expanding. This hub maps the conditions, the evidence, and what is and isn't FDA-approved.

What "FDA-approved" vs "off-label" means here

An FDA-approved indication means the agency has reviewed safety and efficacy data and authorized labeling for that condition. Off-label use is legal, common, and frequently appropriate; it means the medication is prescribed for a condition the FDA has not specifically reviewed for that drug. For GLP-1s, off-label use for PCOS, MASH, and certain other indications is supported by emerging trial data and clinical practice but not by FDA-approved labeling.

How telehealth providers approach these conditions

Most cash-pay telehealth providers, including those we review, write compounded GLP-1 prescriptions primarily for weight management or to support cardiometabolic health, regardless of which underlying condition the patient also has. A patient with T2D, PCOS, or MASLD considering compounded GLP-1 should discuss with their prescriber whether telehealth, traditional primary care, or specialty care is the right fit for their situation.

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.